Iranian Journal of Pathology

Prognostic Significance of lncRNA ATB and SNHG16 Expression Levels in Patients with Hepatocellular Carcinoma

Document Type : Original Research

Authors

sahar Ravanshad 1
Mohammadhossein Taherynejad 2
Zohre Gerami 1
Amin Dalili 3
Hossein Ayatollahi 4
Hassan Mehrad-Majd 4, 5

1 Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

4 Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Clinical Research Development Unit, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences

https://doi.org/10.30699/ijp.2025.2044199.3368
Abstract
Background & Objective: Long noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides, a major component of noncoding RNAs. Previous studies have shown the oncogenic role of various lncRNAs. This study aimed to explore the expression and prognostic value of ATB and SNHG16 in patients with hepatocellular carcinoma.
Methods: ATB and SNHG16 expression in tumor and adjacent normal tissues was identified using real-time quantitative PCR. In this study, patients were divided into 2 groups based on the expression level of each gene, and the correlation between expression level and clinicopathological features of patients with HCC was investigated. All data were analyzed using SPSS version 22.
Results: Of the lncRNAs examined in this study, ATB was expressed at significantly higher levels in tumor tissues. However, this overexpression was not associated with any clinicopathological features of HCC patients.
Conclusion: In this study, overexpression of ATB and SNHG16 was not associated with survival rate or clinicopathological features of patients with hepatocellular carcinoma.

Keywords

Hepatocellular Carcinoma
Long Noncoding RNAs
Tumor

Subjects

  1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. [DOI:10.1038/s41572-020-00240-3] [PMID]
  2. Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015;3(4):732-6. [DOI:10.3889/oamjms.2015.111] [PMID] [PMCID]
  3. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):938-45, 45.e1-4. [DOI:10.1016/j.cgh.2007.02.039] [PMID]
  4. Marengo A, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med. 2016;67:103-17. [DOI:10.1146/annurev-med-090514-013832] [PMID]
  5. Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12): 1898-907. [DOI:10.1038/s12276-020-00527-1] [PMID] [PMCID]
  6. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411-28. [DOI:10.1038/s41575-019-0145-7] [PMID]
  7. Calderon-Martinez E, Landazuri-Navas S, Vilchez E, Cantu-Hernandez R, Mosquera-Moscoso J, Encalada S, et al. Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review. J Clin Med Res. 2023;15(4):200-7. [DOI:10.14740/jocmr4902] [PMID] [PMCID]
  8. Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28(2):216-29. [DOI:10.3748/wjg.v28.i2.216] [PMID] [PMCID]
  9. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(5):870-7. [DOI:10.1016/j.cgh.2013.09.053] [PMID] [PMCID]
  10. Wang T, Zhang KH. New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma. Front Oncol. 2020;10:1316. [DOI:10.3389/fonc.2020.01316] [PMID] [PMCID]
  11. Sayed GI, Solyman M, El Gedawy G, Moemen YS, Aboul-Ella H, Hassanien AE. Circulating miRNA's biomarkers for early detection of hepatocellular carcinoma in Egyptian patients based on machine learning algorithms. Scientific Reports. 2024;14(1): 4989. [DOI:10.1038/s41598-024-54795-2] [PMID] [PMCID]
  12. Eun JW, Cheong JY, Jeong J-Y, Kim HS. A New Understanding of Long Non-Coding RNA in Hepatocellular Carcinoma-From m6A Modification to Blood Biomarkers. Cells. 2023;12(18):2272. [DOI:10.3390/cells12182272] [PMID] [PMCID]
  13. Alessio E, Bonadio RS, Buson L, Chemello F, Cagnin S. A Single Cell but Many Different Transcripts: A Journey into the World of Long Non-Coding RNAs. Int J Mol Sci. 2020;21(1). [DOI:10.3390/ijms21010302] [PMID] [PMCID]
  14. Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10(6):925-33. [DOI:10.4161/rna.24604] [PMID] [PMCID]
  15. Huang Y, Liu N, Wang JP, Wang YQ, Yu XL, Wang ZB, et al. Regulatory long non-coding RNA and its functions. J Physiol Biochem. 2012;68(4):611-8. [DOI:10.1007/s13105-012-0166-y] [PMID] [PMCID]
  16. DiStefano JK. The Emerging Role of Long Noncoding RNAs in Human Disease. Methods Mol Biol. 2018; 1706:91-110. [DOI:10.1007/978-1-4939-7471-9_6] [PMID]
  17. Li J, Li Z, Zheng W, Li X, Wang Z, Cui Y, et al. LncRNA-ATB: An indispensable cancer-related long noncoding RNA. Cell Prolif. 2017;50(6). [DOI:10.1111/cpr.12381] [PMID] [PMCID]
  18. Yang M, Wei W. SNHG16: A Novel Long-Non Coding RNA in Human Cancers. Onco Targets Ther. 2019;12:11679-90. [DOI:10.2147/OTT.S231630] [PMID] [PMCID]
  19. Huang Z, Zhou J-K, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Molecular Cancer. 2020;19(1):77. [DOI:10.1186/s12943-020-01188-4] [PMID] [PMCID]
  20. Mak L-Y, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, et al. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. American Society of Clinical Oncology Educational Book. 2018(38):262-79. [DOI:10.1200/EDBK_200939] [PMID]
  21. Zhang B, Wang D, Ji TF, Shi L, Yu JL. Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-κB signaling pathway in a rat model. Oncotarget. 2017;8(10):17347-59. [DOI:10.18632/oncotarget.14468] [PMID] [PMCID]
  22. Shi C, Zhang L, Qin C. Long non-coding RNAs in brain development, synaptic biology, and Alzheimer's disease. Brain Res Bull. 2017;132:160-9. [DOI:10.1016/j.brainresbull.2017.03.010] [PMID]
  23. Qian Y, Shi L, Luo Z. Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy. Front Med (Lausanne). 2020;7:612393. [DOI:10.3389/fmed.2020.612393] [PMID] [PMCID]
  24. Olufunmilayo EO, Holsinger RMD. Roles of Non-Coding RNA in Alzheimer's Disease Pathophysiology. International Journal of Molecular Sciences. 2023;24(15):12498. [DOI:10.3390/ijms241512498] [PMID] [PMCID]
  25. Tanwar VS, Reddy MA, Natarajan R. Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications. Front Endocrinol (Lausanne). 2021;12:665811. [DOI:10.3389/fendo.2021.665811] [PMID] [PMCID]
  26. Liang W, Zhao Y, Meng Q, Jiang W, Deng S, Xue J. The role of long non-coding RNA in hepatocellular carcinoma. Aging (Albany NY). 2024;16(4):4052-73. [DOI:10.18632/aging.205523] [PMID] [PMCID]
  27. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25(5): 666-81. [DOI:10.1016/j.ccr.2014.03.010] [PMID]
  28. Qu S, Yang X, Song W, Sun W, Li X, Wang J, et al. Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol. 2016;37(3):3933-8. [DOI:10.1007/s13277-015-4252-y] [PMID]
  29. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6(13):11652-63. [DOI:10.18632/oncotarget.3457] [PMID] [PMCID]
  30. Xiong J, Liu Y, Jiang L, Zeng Y, Tang W. High expression of long non-coding RNA lncRNA-ATB is correlated with metastases and promotes cell migration and invasion in renal cell carcinoma. Jpn J Clin Oncol. 2016;46(4):378-84. [DOI:10.1093/jjco/hyv214] [PMID] [PMCID]
  31. Yue B, Qiu S, Zhao S, Liu C, Zhang D, Yu F, et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis. J Gastroenterol Hepatol. 2016;31(3): 595-603. [DOI:10.1111/jgh.13206] [PMID]
  32. Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H, et al. A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res. 2015;35(3):1385-8. [PMID]
  33. Wang CZ, Yan GX, Dong DS, Xin H, Liu ZY. LncRNA-ATB promotes autophagy by activating Yes-associated protein and inducing autophagy-related protein 5 expression in hepatocellular carcinoma. World J Gastroenterol. 2019;25(35):5310-22.[PMID] [PMCID] [DOI:10.3748/wjg.v25.i35.5310]
  34. Jang SY, Kim G, Park SY, Lee YR, Kwon SH, Kim HS, et al. Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma. Oncotarget. 2017;8(45):78588-97. [DOI:10.18632/oncotarget.21094] [PMID] [PMCID]
  35. Zhang QJ, Li DZ, Lin BY, Geng L, Yang Z, Zheng SS. SNHG16 promotes hepatocellular carcinoma development via activating ECM receptor interaction pathway. Hepatobiliary Pancreat Dis Int. 2022;21(1): 41-9. [DOI:10.1016/j.hbpd.2021.09.006] [PMID]
Iranian Journal of Pathology
Volume 20, Issue 2
Spring 2025
Pages 152-158

  • Receive Date 25 October 2024
  • Revise Date 15 February 2025
  • Accept Date 01 March 2025

Home

Guide for Authors

Submit Manuscript

Contact Us